Phase 3 trial shows UGN-102 provides durable complete response in recurrent bladder cancer, suggesting a new treatment option.
Patients who achieved CR following UGN-102 treatment had a high probability of remaining event-free 24 months later. These data indicate UGN-102 is a novel, nonsurgical treatment that provides a durable CR for patients with recurrent LG-IR-NMIBC. Study limitations included the single-arm design and the limited racial diversity of the patients.
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: